Author:
Choi Yong Kee,Adham Nika,Kiss Béla,Gyertyán István,Tarazi Frank I.
Abstract
IntroductionAll clinically effective antipsychotics are known to act on the dopaminergic system, and previous studies have demonstrated that repeated treatment with antipsychotics produced region-specific changes in dopamine receptor levels. Cariprazine is a dopamine D3 and D2 receptor partial agonist with preferential binding to D3 receptors. We examined the effects of chronic cariprazine administration on dopamine receptor levels.MethodsRats were administered either vehicle or cariprazine (0.06, 0.2, or 0.6 mg/kg) for 28 days. Dopamine receptor levels were quantitated using autoradiographic assays on brain tissue sections from the medial prefrontal cortex (mPFC), nucleus accumbens (NAc), caudate putamen (CPu), hippocampus (HIPP), olfactory tubercle (OT), and islands of Calleja (ICj).ResultsChronic treatment with cariprazine did not alter D1 receptor levels in any brain region tested. Cariprazine increased D2 receptor levels in mPFC (27%–43%), NAc (40%–45%), medial (41%–53%) and lateral (52%–63%) CPu, and HIPP (38%). Cariprazine dose-dependently upregulated D3 receptor levels in ICj (32%–57%), OT (27%–67%), and NAc shell (31%–48%). Repeated cariprazine treatment increased D4 receptor in NAc (53%–82%), medial (54%–98%) and lateral (58%–74%) CPu, and HIPP (38%–98%).ConclusionSimilar to other antipsychotics, cariprazine upregulated D2 and D4 receptor levels in various brain regions. Cariprazine was unique among antipsychotics in increasing D3 receptor levels, which may support its unique psychopharmacologic properties.
Publisher
Cambridge University Press (CUP)
Subject
Psychiatry and Mental health,Neurology (clinical)
Reference53 articles.
1. Brain-derived neurotrophic factor controls dopamine D3 receptor expression: Implications for neurodevelopmental psychiatric disorders
2. Long-term effects of olanzapine, risperidone, and quetiapine on dopamine receptor types in regions of rat brain: implications for antipsychotic drug treatment;Tarazi;J Pharmacol Exp Ther,2001
3. Effects of alkylating agents on dopamine D3 receptors in rat brain: selective protection by dopamine
4. Cutler AJ , Bose A , Durgam S , etal. Safety and tolerability of cariprazine in the long-term treatment of schizophrenia: results from a 48-week extension study. Paper presented at: American Psychiatric Association (APA)—165th Annual Meeting; May 5–9, 2012; Philadelphia, PA.
5. Starace A , Bose A , Wang Q , etal. Cariprazine in the treatment of acute mania in bipolar disorder: a double-blind, placebo-controlled, Phase III trial. Paper presented at: American Psychiatric Association (APA)—165th Annual Meeting; May 5–9, 2012; Philadelphia, PA.
Cited by
75 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献